# Reprieve Cardiovascular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reprieve-cardiovascular

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.reprievecardio.com
- Total disclosed funding: $58M
- Latest round: Series B (May 28, 2025)
- Investors on record: 7

## About

Reprieve Cardiovascular, Inc. is a US-based company that specializes in automated fluid management technologies, specifically designed to improve the treatment protocols for Acute Heart Failure patients.Founded in 2018, Reprieve Cardiovascular, Inc. focuses on developing innovative solutions for heart failure management. In August 2025, Reprieve Cardiovascular, Inc. raised USD 61 million in series B funding led by returning investor Deerfield Management, with participation from other returning investors Arboretum Ventures, Lightstone Ventures, Sante Ventures, and Genesis Capital. New investors Rex Health Ventures, Cadence Capital Management, and other unspecified investors also participated in the round. Jim Dillon serves as the CEO and has a background in healthcare technology ventures.Reprieve Cardiovascular primarily offers an innovative automated fluid management technology designed to enhance the treatment of Acute Heart Failure (HF) patients. Their core product, the Reprieve System, integrates real-time patient data with established medical practices to optimize diuretic management. This technology provides physicians and care teams with comprehensive visibility and control over treatment protocols, aimed at addressing the urgent need for precise fluid management in heart failure patients. The system is tailored for use in clinical settings across the United States, where healthcare professionals navigate the complexities of diuretic administration to prevent complications such as kidney injury while ensuring effective fluid removal. The end-users of this service include hospitals and healthcare providers specializing in cardiac care, who seek to improve patient outcomes amid the rising prevalence of heart failure.Reprieve Cardiovascular generates revenue primarily through partnerships with healthcare institutions and potential subscription models for the use of their Reprieve System. The company’s transaction structure involves direct agreements with hospitals and healthcare systems that wish to implement their fluid management technology. These agreements encompass initial setup costs and ongoing fees associated with the use of the Reprieve System, including maintenance and software updates. Specific pricing details have not been disclosed, but the company aims to establish a sustainable revenue stream through direct engagement with healthcare providers committed to improving heart failure management. As the Reprieve System is still in investigational use, further developments in revenue structures are anticipated as the technology progresses toward wider implementation. The company plans to utilize the August 2025 funding to expedite the FASTR II trial and prepare for commercialization.

## Funding rounds

- Series B, May 28, 2025, $31M — Arboretum Ventures, Sante Ventures, Deerfield Management, Lightstone Ventures, Genesis Capital, Rex Health Ventures, Cadence Healthcare Ventures
- Series A, Nov 9, 2023, $12M — Arboretum Ventures, Sante Ventures, Deerfield Management, Lightstone Ventures, Genesis Capital
- Series A, Jul 22, 2020, $15M — Sante Ventures, Deerfield Management

## Investors

- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A, Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A, Series B
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series A, Series B
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A, Series B
- Genesis Capital — Series A, Series B
- Rex Health Ventures (https://capitalatlas.ai/funds/rex-health-ventures) — Series B
- Cadence Healthcare Ventures — Series B